Evidence map›Paper›PMID 31726028›Full record

ArticleCell host & microbe2019

Protective Immunity against Severe Malaria in Children Is Associated with a Limited Repertoire of Antibodies to Conserved PfEMP1 Variants.

Sofonias K Tessema, Rie Nakajima, Algis Jasinskas, Stephanie L Monk, Lea Lekieffre, Enmoore Lin, Benson Kiniboro, Carla Proietti, Peter Siba, Philip L Felgner and 3 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cell host & microbe, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 69 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Antibody levels to variant and conservedFrontiers in immunology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Frontiers in cellular and infection microbiology · 2024
    Article
  15. Natural killer cell antibody-dependent cellular cytotoxicity toClinical & translational immunology · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Sofonias K TessemaDivision of Population Health and Immunity, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Melbourne 3000, VIC, Australia.
Rie NakajimaPhysiology & Biophysics Department, Vaccine R&D Center, University of California, Irvine, Irvine 92697, CA, USA.
Algis JasinskasPhysiology & Biophysics Department, Vaccine R&D Center, University of California, Irvine, Irvine 92697, CA, USA.
Stephanie L MonkDivision of Population Health and Immunity, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Melbourne 3000, VIC, Australia.
Lea LekieffreInfectious Diseases Programme, QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia.
Enmoore LinVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka 441, EHG, Papua New Guinea.
Benson KiniboroVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka 441, EHG, Papua New Guinea.
Carla ProiettiInfectious Diseases Programme, QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia; Australian Institute of Tropical Health and Medicine, James Cook University, Cairns 4878, QLD, Australia.
Peter SibaVector Borne Diseases Unit, Papua New Guinea Institute of Medical Research, Goroka 441, EHG, Papua New Guinea.
Philip L FelgnerPhysiology & Biophysics Department, Vaccine R&D Center, University of California, Irvine, Irvine 92697, CA, USA.
Denise L DoolanInfectious Diseases Programme, QIMR Berghofer Medical Research Institute, Brisbane 4006, QLD, Australia; Australian Institute of Tropical Health and Medicine, James Cook University, Cairns 4878, QLD, Australia.
Ivo MuellerDivision of Population Health and Immunity, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Melbourne 3000, VIC, Australia; Department of Parasites and Insect Vectors, Institut Pasteur, Paris 75015, France.
Alyssa E BarryDivision of Population Health and Immunity, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, VIC, Australia; Department of Medical Biology, University of Melbourne, Melbourne 3000, VIC, Australia. Electronic address: a.barry@deakin.edu.au.
Papua New Guinea Institute of Medical Research · PGQIMR Berghofer Medical Research Institute · AUUniversity of California, Irvine · USWalter and Eliza Hall Institute of Medical Research · AUInstitut Pasteur · FRUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extreme diversity of the major Plasmodium falciparum antigen, PfEMP1, poses a barrier to identifying targets of immunity to malaria. Here, we used protein microarrays containing hundreds of variants of the DBLα domain of PfEMP1 to cover the diversity of Papua New Guinean (PNG) parasites. Probing the plasma of a longitudinal cohort of malaria-exposed PNG children showed that group 2 DBLα antibodies were moderately associated with a lower risk of uncomplicated malaria, whereas individual variants were only weakly associated with clinical immunity. In contrast, antibodies to 85 individual group 1 and 2 DBLα variants were associated with a 70%-100% reduction in severe malaria. Of these, 17 variants were strong predictors of severe malaria. Analysis of full-length PfEMP1 sequences from PNG samples shows that these 17 variants are linked to pathogenic CIDR domains. This suggests that whereas immunity to uncomplicated malaria requires a broad repertoire of antibodies, immunity to severe malaria targets a subset of conserved variants. These findings provide insights into antimalarial immunity and potential antibody biomarkers for disease risk.

Indexed as

Antibodies, ProtozoanAntigens, ProtozoanChild, PreschoolFemaleHumansInfantLongitudinal StudiesMalaria, FalciparumMalaria VaccinesMalePapua New GuineaPlasmodium falciparumProtein Array AnalysisProtein DomainsProtozoan ProteinsAntibodies, ProtozoanAntigens, Protozoanerythrocyte membrane protein 1, Plasmodium falciparumMalaria VaccinesProtozoan ProteinsantibodiesbiomarkerdiversityimmunitymalariaPfEMP1Plasmodium falciparumsevere malariavaccinevar genes

Identifiers

PMID31726028
OpenAlexW2987951717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.